European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
European regulators green light new Alzheimer's drug after first rejecting it
European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved.
ScienceAlert on MSN1d
Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's
University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...
STAT2d
Mild Alzheimer’s patients won’t save Cassava Sciences
As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, ...
‘The Unicorn' at UNTHSC is a gamechanger, say Alzheimer's researchers
Researchers say ‘the Unicorn,’ their invention at the University of Texas Health Science Center, is a game-changer in the ...
New drug targets for Alzheimer's identified from cerebrospinal fluid
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
KPBS13h
Study links heavy drinking to faster Alzheimer’s onset and progression
A new Scripps Research study highlights the link between heavy alcohol use and the acceleration of Alzheimer’s disease.
'We are very hopeful' | New nasal spray could delay Alzheimer's by years, researchers say
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
BioTechniques1d
Untangling the role of TYK2 in Alzheimer’s disease tau pathology
Researchers have revealed the role of enzyme TYK2 in the aggregation of tau proteins, which contributes to Alzheimer’s ...
WJTV Jackson on MSN21h
Alzheimer’s Awareness Month in Mississippi
November is Alzheimer’s Awareness Month. According to the Alzheimer’s Association Mississippi Chapter, nearly 7 million ...
Phoenix-based Banner Health receives $74.5 million grant to study Alzheimer's
The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.